ArticleBlood advances2026
Dynamic monitoring of circulating cell-free EBV-DNA for risk assessment in early-stage natural killer/T-cell lymphoma.
Article in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hydroa Vacciniforme-Like Lymphoproliferative Disorder in the Elderly: A Case Report and Diagnostic Challenges.International medical case reports journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractAlthough circulating tumor DNA has shown promise in real-time monitoring of recurrence risk in various solid tumors, the clinical relevance of cell-free Epstein-Barr virus (EBV) DNA (cfEBV-DNA) in natural killer/T-cell lymphoma (NKTCL) remains unclear. In this study, 710 consecutive patients with early-stage NKTCL were included from 5 hospitals between January 2014 and December 2022, all of whom underwent longitudinal monitoring of cfEBV-DNA. All patients received asparaginase-based induction chemotherapy (IC) followed by radiation therapy (RT). The pretreatment cfEBV-DNA was positive in 487 patients (68.6%), 258 of whom became negative after the first cycles of IC. During chemotherapy, the percentage of patients becoming cfEBV-DNA-negative increased, whereas the velocity of cfEBV-DNA clearance decreased. Achieving cfEBV-DNA negativity during different treatment phases (post-IC cycle 1 [post-IC1] to post-IC6, and post-RT) was significantly associated with better progression-free survival (PFS) and overall survival (OS) compared with those who remained positive (all P< .01). Subsequently, using unsupervised clustering analysis, patients were classified into 4 cfEBV-DNA response phenotypes: (1) consistently negative, (2) early response, (3) late response, and (4) no response. These cohorts had significantly different 5-year PFS (94%, 83%, 57%, and 18%, respectively; P value for trend < .001) and OS (98%, 91%, 70%, and 33%, respectively; P value for trend < .001). In the Cox multivariable analyses, cfEBV-DNA response phenotype was still independently correlated with PFS and OS. In conclusion, dynamic monitoring of on-treatment cfEBV-DNA provides longitudinally prognostic information in patients with early-stage NKTCL and may have therapy implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.